Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Vericel Corproation (VCEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 718,384
  • Shares Outstanding, K 43,911
  • Annual Sales, $ 90,860 K
  • Annual Income, $ -8,140 K
  • 60-Month Beta 2.93
  • Price/Sales 8.15
  • Price/Cash Flow N/A
  • Price/Book 7.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.08
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.87 +2.33%
on 05/20/19
18.41 -11.79%
on 05/06/19
-0.39 (-2.35%)
since 04/18/19
3-Month
15.87 +2.33%
on 05/20/19
21.00 -22.69%
on 02/26/19
-3.13 (-16.16%)
since 02/20/19
52-Week
8.95 +81.45%
on 07/13/18
21.00 -22.69%
on 02/26/19
+1.89 (+13.17%)
since 05/18/18

Most Recent Stories

More News
Vericel to Present at the 2019 UBS Global Healthcare Conference on Wednesday, May 22, 2019

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...

VCEL : 16.06 (-1.83%)
Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance

MACI Revenue Increased 38% Over First Quarter 2018

VCEL : 16.06 (-1.83%)
Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns

Pivotal U.S. Phase 3 Clinical Study Met Primary and All Secondary Endpoints

VCEL : 16.06 (-1.83%)
MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid(R) in North America

$17.5 million upfront, sales royalties and up to $132.5 million in potential milestones

MDWD : 4.36 (-2.02%)
VCEL : 16.06 (-1.83%)
Will Vericel (VCEL) Report Negative Earnings Next Week? What You Should Know

Vericel (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VCEL : 16.06 (-1.83%)
Vericel to Present at Needham Healthcare Conference

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...

VCEL : 16.06 (-1.83%)
Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Verizon Communications Inc. (NYSE:VZ),...

CYRX : 16.87 (-4.15%)
VZ : 59.53 (+2.48%)
CMO : 8.31 (-1.19%)
APPS : 3.92 (-1.01%)
VCEL : 16.06 (-1.83%)
PRTK : 4.16 (-8.57%)
What Makes Vericel (VCEL) a New Buy Stock

Vericel (VCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

VCEL : 16.06 (-1.83%)
Vericel to Present at Multiple Upcoming Investor Conferences

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences.

VCEL : 16.06 (-1.83%)
Vericel (VCEL) Tops on Q4 Earnings & Sales, Stock Up

Vericel (VCEL) beat estimates for earnings as well as revenues in fourth-quarter 2018. Shares up in pre-market trading.

VCEL : 16.06 (-1.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade VCEL with:

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

2nd Resistance Point 17.18
1st Resistance Point 16.77
Last Price 16.06
1st Support Level 16.15
2nd Support Level 15.94

See More

52-Week High 21.00
Fibonacci 61.8% 16.40
Last Price 16.06
Fibonacci 50% 14.98
Fibonacci 38.2% 13.56
52-Week Low 8.95

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar